Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
Study Details
Study Description
Brief Summary
VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study.
The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to Panblok H7 (dose 3) unadjuvanted in approximately 700 adult participants in order to select one dose formulation to be used for further clinical development. The randomization ratio will be 3:3:1 for Panblok H7 (dose 1) + MF59, Panblok H7 (dose 2) + MF59, and Panblok H7 (dose 3) unadjuvanted, respectively. Each study group will be stratified into the age groups 18-64 years and ≥ 65 years of age.
The study duration for each participant will be approximately 13 months.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
The study duration for each participant will be approximately 13 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Group 1 2 doses, 21 days apart, of Panblok H7 dose 1 + MF59 |
Biological: Panblok + MF59 Dose 1
Pharmaceutical form: suspension for injection Route of administration: intramuscular
|
| Experimental: Group 2 2 doses, 21 days apart, of Panblok H7 dose 2 + MF59 |
Biological: Panblok + MF59 Dose 2
Pharmaceutical form: suspension for injection Route of administration: intramuscular
|
| Active Comparator: Group 3 2 doses, 21 days apart, of Panblok H7 dose 3 unadjuvanted |
Biological: Unadjuvanted Panblok Dose 3
Pharmaceutical form: liquid for injection Route of administration: intramuscular
|
Outcome Measures
Primary Outcome Measures
- Geometric Mean Titers of Hemagglutination inhibition (HAI) Antibody (Ab) titers in participants [At Day 22]
HAI Ab titers obtained on Day 22 for comparison with Day 01, Day 202 and Day 387 by HIH measurement method
- Geometric Mean Titers of Hemagglutination inhibition (HAI) Antibody (Ab) titers in participants [At Day 43]
HAI Ab titers obtained on Day 43 for comparison with Day 01, Day 202 and Day 387 by HIH measurement method
- Geometric Mean of individual Ratio (GMR) of HAI Ab titers in participants [At Day 22]
Individual HAI Ab titers ratio Day 22/Day 01 (baseline) by HIH measurement method
- Geometric Mean of individual Ratio (GMR) of HAI Ab titers in participants [At Day 43]
Individual HAI Ab titers ratio Day 43/Day 01 (baseline) by HIH measurement method
- Geometric Mean of individual Ratio (GMR) of HAI Ab titers in participants [At Day 202]
Individual HAI Ab titers ratio Day 202/Day 01 (baseline) by HIH measurement method
- Geometric Mean of individual Ratio (GMR) of HAI Ab titers in participants [At Day 387]
Individual HAI Ab titers ratio Day 387/ Day 01 (baseline) by HIH measurement method
- Percentage of participants with seroconversion [At 21 days after each vaccination]
Seroconversion: defined as titer < 10 (1/dilution [1/dil]) on Day 01 and post-vaccination titer ≥ 40 (1/dil) on Day 22 or Day 43; or titer ≥ 10 (1/dil) on Day 01 and a ≥ 4-fold increase in titer (1/dil) on Day 22 or Day 43 Vaccination taking place on Day 01 and Day 22 by HIH measurement method
- Percentage of participants with HAI titer above predefined threshold [At Day 01]
Participants with HAI Ab titers ≥ 40 (1/dil) by HIH measurement method
- Percentage of participants with HAI titer above predefined threshold [At Day 22]
Participants with HAI Ab titers ≥ 40 (1/dil) by HIH measurement method
- Percentage of participants with HAI titer above predefined threshold [At Day 43]
Participants with HAI Ab titers ≥ 40 (1/dil) by HIH measurement method
- Percentage of participants with HAI titer above predefined threshold [At Day 202]
Participants with HAI Ab titers ≥ 40 (1/dil) by HIH measurement method
- Percentage of participants with HAI titer above predefined threshold [At Day 387]
Participants with HAI Ab titers ≥ 40 (1/dil) by HIH measurement method
- Percentage of participants with detectable HAI Ab titer [At Day 01]
Detectable HAI Ab titer, ie, with a titer ≥ 10 (1/dil) by HIH measurement method
- Percentage of participants with detectable HAI Ab titer [At Day 22]
Detectable HAI Ab titer, ie, with a titer ≥ 10 (1/dil) by HIH measurement method
- Percentage of participants with detectable HAI Ab titer [At Day 43]
Detectable HAI Ab titer, ie, with a titer ≥ 10 (1/dil) by HIH measurement method
- Percentage of participants with detectable HAI Ab titer [At Day 202]
Detectable HAI Ab titer, ie, with a titer ≥ 10 (1/dil) by HIH measurement method
- Percentage of participants with detectable HAI Ab titer [At Day 387]
Detectable HAI Ab titer, ie, with a titer ≥ 10 (1/dil) by HIH measurement method
- Geometric Mean Titers Ratio (GMTR) for Group1/Group3, Group2/Group3, and Group2/Group1 [At 21 days after each vaccination]
Ratio of GMTs for Group1/Group3, Group2/Group3, and Group2/Group1 Vaccination taking place on Day 01 and Day 22 by HIH measurement method
- Geometric Mean Titers of Neutralization (NT) Ab titer in participants [At Day 22]
Neutralization (NT) Ab titer obtained on Day 22 for comparison with D01, D202, and D387 by SN measurement method
- Geometric Mean Titers of Neutralization (NT) Ab titer in participants [At Day 43]
Neutralization (NT) Ab titer obtained on Day 43 for comparison with D01, D202, and D387 by SN measurement method
- Geometric Mean of individual Ratio (GMR) of NT Ab titers in participants [At Day 22]
Individual NT Ab titer ratio Day 22/Day 01 (baseline) by SN measurement method
- Geometric Mean of individual Ratio (GMR) of NT Ab titers in participants [At Day 43]
Individual NT Ab titer ratio Day 43/Day 01 (baseline) by SN measurement method
- Geometric Mean of individual Ratio (GMR) of NT Ab titers in participants [At Day 202]
Individual NT Ab titer ratio Day 202/Day 01 (baseline) by SN measurement method
- Geometric Mean of individual Ratio (GMR) of NT Ab titers in participants [At Day 387]
Individual NT Ab titer ratio Day 387/Day 01 (baseline) by SN measurement method
- Percentage of participants with NT Ab titer above predefined threshold [At Day 22]
Participants with NT Ab titers ≥ 20 (1/dil), ≥ 40 (1/dil), ≥ 80 (1/dil) on Day 22; compared to Day 01, Day 202, and Day 387 by SN measurement method
- Percentage of participants with NT Ab titer above predefined threshold [At Day 43]
Participants with NT Ab titers ≥ 20 (1/dil), ≥ 40 (1/dil), ≥ 80 (1/dil) on Day 43; compared to Day 01, Day 202, and Day 387 by SN measurement method
- Percentage of participants with fold-increase in NT Ab titer [At 21 days after each vaccination]
Fold-increase in NT Ab titer [post/pre] ≥ 2 and ≥ 4 on Day 22 and Day 43, as compared to D01 Vaccination taking place on Day 01 and Day 22 by SN measurement method
- Percentage of participants with detectable NT Ab titer [At Day 01]
Detectable NT Ab titer, ie, with a titer ≥ 10 (1/dil) by SN measurement method
- Percentage of participants with detectable NT Ab titer [At Day 22]
Detectable NT Ab titer, ie, with a titer ≥ 10 (1/dil) by SN measurement method
- Percentage of participants with detectable NT Ab titer [At Day 43]
Detectable NT Ab titer, ie, with a titer ≥ 10 (1/dil) by SN measurement method
- Percentage of participants with detectable NT Ab titer [At Day 202]
Detectable NT Ab titer, ie, with a titer ≥ 10 (1/dil) by SN measurement method
- Percentage of participants with detectable NT Ab titer [At Day 387]
Detectable NT Ab titer, ie, with a titer ≥ 10 (1/dil) by SN measurement method
- GMR for Group1/Group3, Group2/Group3, and Group2/Group1 [At 21 days after each vaccination]
Ratio of GMs for Group1/Group3, Group2/Group3, and Group2/Group1 Vaccination taking place on Day 01 and Day 22 by SN measurement method
Secondary Outcome Measures
- Number of participants with immediate adverse events (AEs) [Within 30 minutes after each vaccination]
Immediate adverse events are any unsolicited systemic adverse events
- Number of participants with solicited injection site and systemic reactions [Up to 7 days after each/any vaccination]
Solicited injection site reactions include injection site pain, erythema, swelling, induration, ecchymosis Solicited systemic reactions include fever, headache, malaise, myalgia
- Number of participants with unsolicited AEs [Up to 21 days after each/any vaccination]
Unsolicited (spontaneously reported) AEs, not fulfilling criteria for solicited adverse reactions
- Number of participants with medically adverse events (MAAEs) [From Day 01 up to Day 387]
MAAEs
- Number of participants with adverse events of special interest (AESIs) [From Day 01 up to Day 387]
AESIs
- Number of participants with serious adverse events (SAEs) (including AESIs) [From Day 01 up to Day 387]
SAEs (including AESIs)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged 18 years or older on the day of inclusion
-
Participants who are healthy as determined by medical evaluation including medical history and physical examination
-
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile.
OR Is of childbearing potential and agrees to use a highly effective contraceptive method or abstinence from at least 4 weeks prior to each study intervention administration until at least 12 weeks after the last study intervention administration.
-
A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 24 hours before the first dose of study intervention
-
Informed consent form has been signed and dated
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
-
Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
-
Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
-
Thrombocytopenia or bleeding disorder contraindicating intramuscular injection based on investigator's judgement
-
Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion (1)
(1) Chronic illness may include, but is not limited to, cardiac disorders, renal disorders, auto-immune disorders, diabetes, psychiatric disorders, or chronic infection
-
Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that is stable at the time of study intervention administration in the absence of therapy, and participants who have a history of neoplastic disease and who have been disease-free for ≥ 5 years)
-
Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 100.4°F) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
-
Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
-
Receipt of any vaccine in the 14 days preceding Visit 1 or planned receipt of any vaccine prior to Visit 3, except for seasonal flu vaccine, which may be received at least 2 weeks after Visit 2
-
Previous vaccination against H7N9 with an investigational vaccine
-
Receipt of immune globulins, blood or blood-derived products in the past 3 months
-
Participation at the time of study enrollment (or in the 4 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
-
Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
-
Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study
-
Personal or family history of Guillain-Barré syndrome
-
Self-reported seropositivity for Hepatitis B antigen or Hepatitis C
"The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial."
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Aventiv Research Mesa-Site Number:8400006 | Mesa | Arizona | United States | 85210 |
| 2 | Velocity Clinical Research-Hallandale Beach-Site Number:8400026 | Hallandale Beach | Florida | United States | 33009 |
| 3 | Research Centers of America-Site Number:8400024 | Hollywood | Florida | United States | 33024 |
| 4 | Suncoast Research Associates, LLC-Site Number:8400008 | Miami | Florida | United States | 33173 |
| 5 | Headlands Research Orlando-Site Number:8400014 | Orlando | Florida | United States | 32819 |
| 6 | St Johns Center for Clinical Research-Site Number:8400021 | Saint Augustine | Florida | United States | 32086 |
| 7 | CRA Headlands Stockbridge-Site Number:8400020 | Stockbridge | Georgia | United States | 30281 |
| 8 | Velocity Clinical Research Valparaiso-Site Number:8400007 | Valparaiso | Indiana | United States | 46383 |
| 9 | MedPharmics-Site Number:8400027 | Metairie | Louisiana | United States | 70006 |
| 10 | M3 Wake Research Inc-Site Number:8400010 | Raleigh | North Carolina | United States | 27612 |
| 11 | Wrightsville Family Practice Pa-Site Number:8400025 | Wilmington | North Carolina | United States | 28403 |
| 12 | Preferred Primary Care Physicians-Site Number:8400015 | Pittsburgh | Pennsylvania | United States | 15236 |
| 13 | Preferred Primary Care Physicians, Inc.-Site Number:8400002 | Pittsburgh | Pennsylvania | United States | 15243 |
| 14 | Velocity Clinical Research Anderson-Site Number:8400016 | Anderson | South Carolina | United States | 29621 |
| 15 | WR-ClinSearch, LLC-Site Number:8400003 | Chattanooga | Tennessee | United States | 37421 |
| 16 | Velocity Clinical Research Cedar Park-Site Number:8400019 | Cedar Park | Texas | United States | 78613 |
Sponsors and Collaborators
- Sanofi Pasteur, a Sanofi Company
Investigators
- Study Director: Clinical Sciences & Operations, MCM Vaccines B.V.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VAM00001
- U1111-1256-9115